INTS Q3 EPS Reduced by Brookline Capital Markets

Intensity Therapeutics Inc. (NASDAQ:INTS) – Stock analysts at Brookline Capital Markets dropped their Q3 2026 earnings per share estimates for Intensity Therapeutics in a research report issued to clients and investors on Friday, August 14th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings per share of ($0.77) for the quarter, down from their prior forecast of ($0.57). The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($2.70) per share. Brookline Capital Markets also issued estimates for Intensity Therapeutics’ Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($3.41) EPS, FY2027 earnings at ($2.41) EPS, FY2028 earnings at ($6.01) EPS and FY2030 earnings at $13.27 EPS.

Intensity Therapeutics (NASDAQ:INTS) last released its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24).

A number of other analysts have also commented on INTS. Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th. Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Intensity Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $37.50.

Intensity Therapeutics Trading Up 4.8%

INTS opened at $4.15 on Tuesday. The firm has a 50 day simple moving average of $4.26 and a 200 day simple moving average of $5.48. Intensity Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $43.50. The company has a market cap of $13.53 million, a price-to-earnings ratio of -0.73 and a beta of 2.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in Intensity Therapeutics by 77.8% in the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after purchasing an additional 201,357 shares in the last quarter. Mesirow Financial Investment Management Inc. boosted its position in shares of Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after purchasing an additional 51,000 shares in the last quarter. Legacy Advisors LLC bought a new position in shares of Intensity Therapeutics during the fourth quarter worth $63,000. State Street Corp grew its holdings in shares of Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after buying an additional 121,700 shares during the period. Finally, Corient Private Wealth LLC acquired a new position in shares of Intensity Therapeutics in the 4th quarter valued at $41,000. Institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.